M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Takeda receives Japanese approval for HYQVIA 10% subcutaneous injection set with ENHANZE for immunodeficiency disorders
Biopharmaceutical company Halozyme Therapeutics Inc (NASDAQ: HALO) announced on Monday that pharmaceutical company Takeda has received regulatory approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search